We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dionex to Purchase ESA Biosciences' HPLC Assets

By LabMedica International staff writers
Posted on 18 Sep 2009
Print article
Dionex Corporation (Sunnyvale, CA, USA), a provider of liquid chromatography analysis systems, has entered into an asset purchase agreement with ESA Biosciences (Chelmsford, MA, USA), a wholly owned subsidiary of Magellan Biosciences, Inc. Dionex will purchase ESA Biosciences high performance liquid chromatography (HPLC) products, HPLC clinical assays, and laboratory services.

The agreement will give Dionex three lines of HPLC detectors. These products include the Corona universal charged aerosol detectors, which Dionex will sell with its own HPLC equipment or directly on third party systems. The other two product lines, the CoulArray and Coulocheme electrochemical detectors are targeted at clinical, metabolomics, and neuroscience applications.

Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position it as a leading provider of comprehensive electrochemistry solutions for liquid chromatography.

The terms of the transaction were not disclosed. Dionex anticipates that the transaction will generate additional revenue of US$12-$15 million and excluding one time charges will be slightly accretive in fiscal 2010. The transaction is expected to close by the end of September 2009.

Dionex is a manufacturer and marketer of ion chromatography, HPLC and sample preparation systems, accessories and consumables, and software products for chemical and life sciences applications. Dionex provides application solutions ranging from the identification and measurement of inorganic and organic ions, small organic molecules, as well as large biomolecules.

ESA Biosciences designs and manufactures a full range of specialty detectors, reagents, and total solutions. The products are used in neuroscience, clinical diagnostic, biomedical research, and industrial laboratories worldwide. Through its subsidiary, ESA Laboratories, Inc., the company also provides a range of analytical services ranging from industrial hygiene and clinical diagnostic analysis, to metabolomics profiling.

Related Links:

Dionex Corporation
ESA Biosciences


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
HbA1c Test
HbA1c Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.